Medullary Thyroid Cancer - Pipeline Review, H2 2013


#172122

75pages

Global Markets Direct

$ 2000

In Stock


Global Markets Directs, Medullary Thyroid Cancer Pipeline Review, H2 2013, provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Medullary Thyroid Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Medullary Thyroid Cancer. Medullary Thyroid Cancer Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Medullary Thyroid Cancer.
  • A review of the Medullary Thyroid Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Medullary Thyroid Cancer pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Medullary Thyroid Cancer.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Medullary Thyroid Cancer pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents

Table of Contents 2

List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Medullary Thyroid Cancer Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Medullary Thyroid Cancer 7
Medullary Thyroid Cancer Therapeutics under Development by Companies 9
Medullary Thyroid Cancer Therapeutics under Investigation by Universities/Institutes 10
Late Stage Products 11
Comparative Analysis 11
Mid Clinical Stage Products 12
Comparative Analysis 12
Pre-Clinical Stage Products 13
Comparative Analysis 13
Medullary Thyroid Cancer Therapeutics Products under Development by Companies 14
Medullary Thyroid Cancer Therapeutics Products under Investigation by Universities/Institutes 15
Companies Involved in Medullary Thyroid Cancer Therapeutics Development 16
AstraZeneca PLC 16
Novartis AG 17
Exelixis, Inc. 18
OXiGENE, Inc. 19
Globeimmune, Inc. 20
Jiangsu Chia Tai-Tianqing Pharmaceutical Co., Ltd. 21
Medullary Thyroid Cancer Therapeutics Assessment 22
Assessment by Monotherapy Products 22
Assessment by Route of Administration 23
Assessment by Molecule Type 25
Drug Profiles 27
pasireotide - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
vandetanib - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
vandetanib - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
cabozantinib (S)-malate - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
GI-6207 - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
lithium carbonate - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
anlotinib hydrochloride - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
CLM-29 - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
Medullary Thyroid Cancer Therapeutics Drug Profile Updates 49
Medullary Thyroid Cancer Therapeutics - Dormant Products 66
Medullary Thyroid Cancer Product Development Milestones 67
Featured News & Press Releases 67
Jun 02, 2013: Exelixis Presents Cometriq Clinical Trial Data In Patients With Progressive, Metastatic Medullary Thyroid Cancer 67
May 07, 2013: Exelixis To Feature Nine Presentations On Cabozantinib At 2013 ASCO Annual Meeting 68
Apr 08, 2013: Ariad Pharma Presents New Preclinical Data On Ponatinib At AACR Annual Meeting 2013 69
Apr 03, 2013: GlobeImmune Initiates Phase II Study Of New T Cell Stimulating Cancer Vaccine Targeting CEA In Patients With Metastatic Medullary Thyroid Cancer 70
Feb 14, 2013: Eisais Thyroid Cancer Drug Candidate Lenvatinib Obtains FDA Orphan Drug Status 71
Jan 24, 2013: Exelixiss Cometriq Is Now Available In US 71
Dec 07, 2012: Catalent Pharma To Supply FDA Approved Exelixiss Cometriq In US Market 71
Nov 29, 2012: Exelixis Announces EMA Acceptance Of Marketing Authorization Application For Thyroid Cancer Drug Cometriq 72
Nov 29, 2012: Exelixiss Cometriq Obtains FDA Approval For Treatment Of Metastatic Medullary Thyroid Cancer 72
Sep 17, 2012: Exelixis Announces Data Presentations On Cabozantinib At ESMO 2012 Congress 73

Appendix 74
Methodology 74
Coverage 74
Secondary Research 74
Primary Research 74
Expert Panel Validation 74
Contact Us 75
Disclaimer 75

Number of Products Under Development for Medullary Thyroid Cancer, H2 2013 7
Products under Development for Medullary Thyroid Cancer Comparative Analysis, H2 2013 8
Number of Products under Development by Companies, H2 2013 9
Number of Products under Investigation by Universities/Institutes, H2 2013 10
Comparative Analysis by Late Stage Development, H2 2013 11
Comparative Analysis by Mid Clinical Stage Development, H2 2013 12
Comparative Analysis by Pre-Clinical Stage Development, H2 2013 13
Products under Development by Companies, H2 2013 14
Products under Investigation by Universities/Institutes, H2 2013 15
AstraZeneca PLC, H2 2013 16
Novartis AG, H2 2013 17
Exelixis, Inc., H2 2013 18
OXiGENE, Inc., H2 2013 19
Globeimmune, Inc., H2 2013 20
Jiangsu Chia Tai-Tianqing Pharmaceutical Co., Ltd., H2 2013 21
Assessment by Monotherapy Products, H2 2013 22
Assessment by Stage and Route of Administration, H2 2013 24
Assessment by Stage and Molecule Type, H2 2013 26
Medullary Thyroid Cancer Therapeutics Drug Profile Updates 49
Medullary Thyroid Cancer Therapeutics Dormant Products 66
Number of Products under Development for Medullary Thyroid Cancer, H2 2013 7
Products under Development for Medullary Thyroid Cancer Comparative Analysis, H2 2013 8
Products under Development by Companies, H2 2013 9
Products under Investigation by Universities/Institutes, H2 2013 10
Late Stage Products, H2 2013 11
Mid Clinical Stage Products, H2 2013 12
Pre-Clinical Stage Products, H2 2013 13
Assessment by Monotherapy Products, H2 2013 22
Assessment by Route of Administration, H2 2013 23
Assessment by Stage and Route of Administration, H2 2013 24
Assessment by Molecule Type, H2 2013 25
Assessment by Stage and Molecule Type, H2 2013 26